Back

Castle Biosciences test posts 97.3% negative predictive value in high-risk SCC study

Verifying
  • Castle Biosciences published a multi-center study validating integrated DecisionDx-SCC results.
  • 44.6% of patients were Class 1A, with a 97.3% negative predictive value.
  • Class 2B patients had 66.2% three-year metastasis-free survival and greater ART benefit.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.